Publication date: Sep 01, 2024
Delayed sputum conversion has been associated with a higher risk of treatment failure or relapse among drug susceptible smear-positive pulmonary tuberculosis patients. Several contributing factors have been identified in many studies, but the results varied across regions and countries. Therefore, the current study aimed to develop a predictive model that explained the factors affecting time to sputum conversion within two months after initiating antituberculosis agents among Malaysian with drug-susceptible smear-positive pulmonary tuberculosis patients. Retrospective data of pulmonary tuberculosis patients followed up at a tertiary hospital in the Northern region of Malaysia from 2013 until 2018 were collected and analysed. Nonlinear mixed-effect modelling software (NONMEM 7. 3.0) was used to develop parametric survival models. The final model was further validated using Kaplan-Meier-visual predictive check (KM-VPC) approach, kernel-based hazard rate estimation method and sampling-importance resampling (SIR) method. A total of 224 patients were included in the study, with 34. 4 % (77/224) of the patients remained positive at the end of 2 months of the intensive phase. Gompertz hazard function best described the data. The hazard of sputum conversion decreased by 39 % and 33 % for moderate and advanced lesions as compared to minimal baseline of chest X-ray severity, respectively (adjusted hazard ratio (aHR), 0. 61; 95 % confidence intervals (95 % CI), (0. 44-0. 84) and 0. 67, 95 % CI (0. 53-0. 84)). Meanwhile, the hazard also decreased by 59 % (aHR, 0. 41; 95 % CI, (0. 23-0. 73)) and 48 % (aHR, 0. 52; 95 % CI, (0. 35-0. 79)) between active and former drug abusers as compared to non-drug abuser, respectively. The successful development of the internally and externally validated final model allows a better estimation of the time to sputum conversion and provides a better understanding of the relationship with its predictors.
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | pulmonary tuberculosis |
disease | MESH | treatment failure |
disease | MESH | relapse |
drug | DRUGBANK | Tropicamide |